Article

In ischemic stroke patients, blood-based biomarkers may be applied for the
diagnosis of ischemic origin and subtype, prediction of outcomes and targeted
treatment in selected patients. Knowledge of the pathophysiology of cerebral
ischemia has led to the evaluation of proteins, neurotransmitters, nucleic acids
and lipids as potential biomarkers. The present report focuses on the role of
blood-based biomarkers in the early stage of ischemic stroke-within 72h of its
onset-as gleaned from studies published in English in such patients. Despite
growing interest in their potential role in clinical practice, the application of
biomarkers for the management of cerebral ischemia is not currently recommended
by guidelines. However, there are some promising clinical biomarkers, as well as
the N-methyl-d-aspartate (NMDA) peptide and NMDA-receptor (R) autoantibodies that
appear to identify the ischemic nature of stroke, and the glial fibrillary acidic
protein (GFAP) that might be able to discriminate between acute ischemic and
hemorrhagic strokes. Moreover, genomics and proteomics allow the characterization
of differences in gene expression, and protein and metabolite production, in
ischemic stroke patients compared with controls and,
thus, may help to identify
novel markers with sufficient sensitivity and specificity. Additional studies to
validate promising biomarkers and to identify novel biomarkers are needed.
CI - Copyright (c) 2016 Elsevier Masson SAS. All rights reserved.

Langue : ANGLAIS